NCT03737994 2026-03-18
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT04318938 2026-03-02
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT04223596 2026-02-04
CUBIK
Fundación GECP
Phase 2 Active not recruiting
NCT05200481 2025-11-17
MP-ALK
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT03535740 2025-07-31
ALTA-2
Takeda
Phase 2 Completed
NCT06522360 2025-04-24
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04322890 2024-10-22
PIKACHU
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05718297 2024-10-08
BOUNCE
ETOP IBCSG Partners Foundation
Phase 2 Withdrawn
NCT05014464 2024-09-20
ATPase
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT03410108 2024-05-08
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
Takeda
Phase 2 Completed
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT04074993 2023-09-28
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
National Cancer Center, Korea
Phase 2 Unknown
NCT04634110 2022-10-24
Brigatinib Before Brain Irradiation Trial (B3i Trial)
University of Colorado, Denver
Phase 2 Terminated
NCT05361564 2022-05-04
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.
Yonsei University
Phase 2 Unknown
NCT02094573 2021-03-15
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Takeda
Phase 2 Completed